“

We've seen a significant slowdown in emerging markets, particularly in Asia, which has led to a corresponding drop in our surgical equipment sales, we've also seen increasing competitive pricing pressure in our IOL business. The third factor ... is the increasing generic pressure that we've had in our U.S. pharma business.